ThermoGenesis Holdings, Inc.

THMO

US88362L2097

Office Equipment

Market Closed - OTC Markets Other stock markets 12:25:31 2025-06-17 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2024	ThermoGenesis Holdings, Inc. Announces Resignation of Jeffery Cauble as Chief Financial Officer	CI
2024	ThermoGenesis Holdings, Inc. Receives A Notice of Default from Boyalife Group, Inc	CI

ThermoGenesis Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

Published on 11/13/2023 at 16:05

ThermoGenesis Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 2.19 million compared to USD 2.12 million a year ago. Net loss was USD 3.62 million compared to USD 3.24 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 4.66 a year ago.
For the nine months, sales was USD 7.04 million compared to USD 7.81 million a year ago. Net loss was USD 10.96 million compared to USD 7.84 million a year ago.

Latest news about ThermoGenesis Holdings, Inc.

ThermoGenesis Holdings, Inc. Announces Resignation of Jeffery Cauble as Chief Financial Officer	24-07-16	CI
ThermoGenesis Holdings, Inc. Receives A Notice of Default from Boyalife Group, Inc	24-07-11	CI
ThermoGenesis Holdings, Inc. Announces Board and Committee Resignations	24-06-26	CI
ThermoGenesis Holdings, Inc.(NasdaqCM:THMO) dropped from S&P TMI Index	24-06-19	CI
ThermoGenesis Holdings, Inc.(OTCPK:THMO) dropped from NASDAQ Composite Index	24-06-13	CI
Wall Street Set to Open Higher Wednesday as Key Inflation Data Lower Than Expected	24-06-12	MT
US Futures Slightly Higher Ahead of Fed's Rate Decision, Key Inflation Data	24-06-12	MT
Top Premarket Decliners	24-06-12	MT
ThermoGenesis Corp. Enters into A Manufacture and Supply Agreement with CBR Systems, Inc	24-06-04	CI
ThermoGenesis Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-05-17	CI
ThermoGenesis Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-16	CI
ThermoGenesis Holdings, Inc. Auditor Raises 'Going Concern' Doubt	24-04-15	CI
North American Morning Briefing : Traders Await -2-	24-04-10	DJ
North American Morning Briefing : Powell Awaited -2-	24-04-03	DJ
Thermogenesis Holdings, Inc. Announces Resignation of Haihong Zhu, Chief Operating Officer and A Director from the Board	24-03-12	CI
ThermoGenesis Files $30 Million Mixed Shelf	23-11-24	MT
ThermoGenesis Holdings, Inc., Q3 2023 Earnings Call, Nov 13, 2023	23-11-13
ThermoGenesis Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-11-13	CI
ThermoGenesis Holdings, Inc. to Open a New 35,500 Square Foot ReadyStart-IncuStart cGMP Facility in Greater Sacramento	23-10-26	CI
ThermoGenesis Holdings, Inc. Announces Management Changes	23-08-29	CI
ThermoGenesis Holdings, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
ThermoGenesis Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
ThermoGenesis Holdings, Inc. announced that it has received $1 million in funding	23-07-30	CI
ThermoGenesis Holdings, Inc. Announces Board Appointments	23-07-19	CI
Top Premarket Gainers	23-06-06	MT

Chart ThermoGenesis Holdings, Inc.

Duration

Period

THMO: Dynamic Chart

Company Profile

ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.

Employees

Sector

Office Equipment

More about the company